TP53 and cancer: In the remaining cancers that retain wild-type p53 (wtp53), p53 function is frequently abolished by the overexpression of p53 inhibitors, such as MDM26 and QCR27, or the silencing of p53 activators, such as BAI18 and LACTB9.